About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases.
Its drug candidate, ALG‑055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.
The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG‑097558, a small molecule ritonavir‑free pan‑coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus.
The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven.
Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.